All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Sacubitril Sodium,Valsartan
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Entresto
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2021
Details:
Entresto's label expansion is based on efficacy and safety evidence observed in PARAGON-HF, the largest and only Phase III active-controlled study to date in patients with guideline-defined HFpEF.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Inclisiran
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Leqvio
Highest Development Status: Approved Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2020
Details:
Approval is based on the results of the robust ORION clinical development program, where Leqvio provided an effective and sustained low-density lipoprotein cholesterol (LDL-C) reduction of up to 52% in patients with elevated LDL-C, despite maximally tolerated statin therapy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): lomitapide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Lojuxta
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Amryt Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 19, 2020
Details:
Under the agreement, Swixx will distribute Lojuxta® from October 2020 in Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Estonia, Kosovo, Latvia, Lithuania, Montenegro, North Macedonia, Poland, Romania, Serbia and Slovakia.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Sacubitril valsartan sodium hydrate
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Otsuka Chemical Co Ltd
Deal Size: Undisclosed Upfront Cash: $90.0 million
Deal Type: Agreement March 02, 2020
Details:
Under the terms of this agreement, Novartis Pharma and Otsuka will jointly undertake the promotion of LCZ696 to healthcare practitioners in Japan.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
